From:  Extracellular vesicles as candidate mediators linking insulin resistance and metabolic dysfunction-associated steatotic liver disease

 Representative EV-based candidate biomarkers in MASLD, with the design and stage of validation stated for each.

Candidate markerCompartmentReported roleDesign and stage of validation
Circulating miR-122, miR-34a, miR-192Serum or plasma, not vesicle-restrictedAssociated with histological severity and hepatocyte ballooningCross-sectional, multiple independent cohorts; not EV-specific
Vesicular liver microRNA and EV proteomePlasma, experimental modelDiscriminated fatty liver disease from controlMurine discovery study; not validated in humans
Fibulin-3Serum EV proteomeCorrelated with fibrosis progression; predicted liver-related eventsProspective outcome cohort; single cohort, external validation outstanding
EV concentration and size distributionPlasma, totalStaging and identification of severe steatosis within machine-learning modelsSingle-cohort model development; cited from secondary literature
EpCAM-positive, CD133-positive EVsSerumDistinguished steatohepatitis from simple steatosisCross-sectional, biopsy-anchored; cited from secondary literature
GLUT1-positive hepatogenic exosomesPlasmaElevated in MASH; proposed for stagingCross-sectional, biopsy-anchored; cited from secondary literature
ASGR1-positive vesicular miR-122, miR-192, miR-128-3pPlasma, liver-specific vesiclesTracked disease severityCross-sectional, biopsy-anchored; cited from secondary literature
Urinary EV lipidomic panelUrineDiscriminated MASH from simple steatosis (AUC approximately 92%)Single-cohort discovery with machine learning; overfitting not excluded

ASGR1: asialoglycoprotein receptor 1; AUC: area under the receiver operating characteristic curve.